HF
VERV

HRT Financial’s Verve Therapeutics VERV Stock Holding History

HRT Financial’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,243
Closed -$202K – 3581
2025
Q1 		$202K Buy
44,243
+13,453
+44% +$90.1K ﹤0.01% 2029
2024
Q4 		$173K Sell
30,790
-96,069
-76% -$542K ﹤0.01% 1971
2024
Q3 		$613K Buy
+126,859
New +$737K ﹤0.01% 1492
2024
Q1 		– Sell
-22,267
Closed -$310K – 3149
2023
Q4 		$310K Buy
+22,267
New +$276K ﹤0.01% 1613
2023
Q3 		– Sell
-12,669
Closed -$237K – 3152
2023
Q2 		$237K Sell
12,669
-1,263
-9% -$21K ﹤0.01% 1758
2023
Q1 		$200K Buy
+13,932
New +$273K ﹤0.01% 1929
2022
Q3 		– Sell
-36,541
Closed -$558K – 3550
2022
Q2 		$558K Buy
+36,541
New +$566K 0.01% 1403
2021
Q3 		– Sell
-62,159
Closed -$3.75M – 3788
2021
Q2 		$3.75M Buy
+62,159
New +$2.58M 0.03% 384

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial's VERV Position: Q2 2025 in Review

HRT Financial sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 44,243 shares — an estimated $202K sold.

HRT Financial first reported a position in VERV in Q2 2021 and held it in 8 quarters. The position peaked at $3.75M in Q2 2021. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • HRT Financial reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 44,243 Verve Therapeutics shares in Q2 2025, an estimated $202K.
  • HRT Financial first reported a position in Verve Therapeutics in Q2 2021 and held it in 8 quarters.
  • HRT Financial's Verve Therapeutics position peaked at $3.75M in Q2 2021.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.